jCyte
US-based jCyte pioneers in progenitor cell technology for retinal diseases, offering non-surgical jCell treatment.
Founded
2012US-based jCyte pioneers in progenitor cell technology for retinal diseases, offering non-surgical jCell treatment.
Founded in Newport Beach, United States, jCyte is a clinical-stage company dedicated to developing innovative therapies for degenerative retinal disorders. Its core mission is to leverage progenitor cell-based technology to treat retinal diseases, aiming to restore vision and improve quality of life for patients. The company's flagship product, jCell, is a non-surgical, allogeneic treatment delivered via intravitreal injection, currently in late-stage clinical development for retinitis pigmentosa and other inherited retinal conditions.
Notable affiliated individuals include leading ophthalmologists and researchers in the field of retinal diseases. jCyte has attracted significant investment from prominent venture capital firms and biotech investors. Key achievements include successful progression through early clinical trials and recognition within the medical community for its pioneering approach. The company’s impact lies in its potential to offer a groundbreaking treatment option for patients with blinding retinal disorders, positioning itself as a leader in ophthalmic regenerative medicine.
Companies similar to jCyte include EyeCyte, ViaCyte, Celularity and Stemedica Cell Technologies.
jCyte was founded in 2012.
jCyte's headquarters is located in Newport Beach, CA, US.
jCyte's most recent funding round was for $3.9M (USD) in March 2019.
As of Mar 15, 2019, jCyte has disclosed funding of $3.9M (USD). Undisclosed round amounts are excluded.
jCyte has 11 employees as of Feb 5, 2024.
stemedica.com
